Free Trial
→ One page of the SpaceX S-1 will move this stock overnight (From Behind the Markets) (Ad)tc pixel Free EYPT Stock Alerts

Eyepoint Pharmaceuticals (EYPT) Financials

Eyepoint Pharmaceuticals logo
$12.93 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$12.92 -0.01 (-0.08%)
As of 05/22/2026 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Eyepoint Pharmaceuticals

Annual Income Statements for Eyepoint Pharmaceuticals

This table shows Eyepoint Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 6.35 -22 -18 -53 -57 -91 -58 -102 -71 -131 -232
Consolidated Net Income / (Loss)		 6.35 -22 -18 -53 -57 -45 -58 -102 -71 -131 -232
Net Income / (Loss) Continuing Operations		 6.35 -22 -18 -53 -57 -91 -58 -102 -71 -131 -232
Total Pre-Tax Income 		6.44 -22 -18 -53 -57 -91 -58 -102 -71 -131 -232
Total Operating Income		 6.42 -22 -19 -26 -48 -37 -55 -100 -75 -146 -243
Total Gross Profit		 27 1.62 7.54 2.96 18 63 29 33 46 43 29
Total Revenue		 27 1.62 7.54 2.96 20 69 37 41 46 43 31
Operating Revenue		 27 1.62 7.54 2.96 20 69 37 41 46 43 31
Total Cost of Revenue		 0.00 0.00 0.00 0.00 2.69 5.82 8.18 8.33 0.00 0.00 2.07
Operating Cost of Revenue		 - - 0.00 0.00 2.69 5.82 8.18 8.33 - - 2.07
Total Operating Expenses		 20 23 26 29 66 138 84 133 121 189 273
Selling, General & Admin Expense		 8.06 9.01 11 12 18 21 26 35 40 52 52
Marketing Expense		 - 0.00 0.00 1.51 30 25 28 26 12 0.13 0.09
Research & Development Expense		 12 14 15 16 15 17 29 50 65 133 221
Amortization Expense		 - - 0.00 0.00 2.46 - 2.46 2.05 0.00 0.00 0.00
Impairment Charge		 - - - - - - 0.00 21 0.00 0.00 0.00
Total Other Income / (Expense), net		 0.02 0.07 0.09 -27 -8.93 -16 -3.14 -2.62 4.36 15 12
Interest Expense		 - 0.00 0.00 0.72 9.99 8.16 3.43 4.75 2.59 0.01 0.03
Other Income / (Expense), net		 0.02 0.07 0.09 -26 1.05 -8.05 0.29 2.13 6.95 15 12
Income Tax Expense		 0.10 -0.16 - - - - - 0.00 0.08 0.09 0.28
Basic Earnings per Share		 $0.22 ($0.68) ($0.52) ($1.15) ($5.44) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Weighted Average Basic Shares Outstanding		 29.38M 31.62M 35.34M 67.94M 10.43M 12.84M 28.76M 37.32M 38.90M 56.30M 73.25M
Diluted Earnings per Share		 $0.21 ($0.68) ($0.52) ($1.15) ($5.44) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Weighted Average Diluted Shares Outstanding		 30.58M 31.62M 35.34M 67.94M 10.43M 12.84M 28.76M 37.32M 38.90M 56.30M 73.25M
Weighted Average Basic & Diluted Shares Outstanding		 28.90M 31.62M 35.34M 46.23M 10.43M 12.84M 28.76M 34.30M 49.83M 68.73M 83.43M

Quarterly Income Statements for Eyepoint Pharmaceuticals

This table shows Eyepoint Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -13 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85
Consolidated Net Income / (Loss)		 -13 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85
Net Income / (Loss) Continuing Operations		 -13 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85
Total Pre-Tax Income 		-13 -14 -29 -31 -29 -41 -45 -59 -60 -67 -85
Total Operating Income		 -14 -16 -33 -35 -33 -45 -49 -62 -62 -70 -87
Total Gross Profit		 14 18 11 9.48 9.79 14 24 5.33 0.97 -1.45 0.70
Total Revenue		 15 14 12 9.48 11 12 24 5.33 0.97 0.62 0.70
Operating Revenue		 15 14 12 9.48 11 12 24 5.33 0.97 0.62 0.70
Total Cost of Revenue		 1.20 -3.63 0.76 0.00 0.74 -2.90 0.81 0.00 0.00 2.07 0.00
Total Operating Expenses		 28 34 44 44 43 60 72 68 63 69 88
Selling, General & Admin Expense		 11 11 14 13 13 13 14 12 14 11 15
Marketing Expense		 0.48 0.19 0.01 0.05 0.02 0.05 0.04 0.04 0.03 -0.01 0.00
Research & Development Expense		 17 18 30 30 30 43 59 55 48 59 72
Other Operating Expenses / (Income)		 - - - 1.40 - - - 0.17 0.72 - 0.53
Total Other Income / (Expense), net		 1.79 2.34 4.04 3.72 3.39 3.93 3.64 2.89 2.29 2.92 2.34
Other Income / (Expense), net		 1.79 2.34 4.04 3.72 3.39 3.94 3.64 2.89 2.29 2.96 2.34
Income Tax Expense		 - - - 0.00 0.00 - 0.00 0.09 0.00 - -0.05
Basic Earnings per Share		 ($0.33) ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99)
Weighted Average Basic Shares Outstanding		 38.34M 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M
Diluted Earnings per Share		 ($0.33) ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99)
Weighted Average Diluted Shares Outstanding		 38.34M 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M
Weighted Average Basic & Diluted Shares Outstanding		 35.31M 49.83M 52.08M 53.52M 68.25M 68.73M 68.81M 68.93M 82.79M 83.43M 83.84M

Annual Cash Flow Statements for Eyepoint Pharmaceuticals

This table details how cash moves in and out of Eyepoint Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.79 -3.81 1.59 22 -23 23 134 -83 186 -182 2.12
Net Cash From Operating Activities		 10 -16 -20 -22 -57 -14 -50 -65 1.88 -126 -240
Net Cash From Continuing Operating Activities		 10 -16 -20 -22 -57 -14 -50 -65 1.88 -126 -240
Net Income / (Loss) Continuing Operations		 6.35 -22 -18 -53 -57 -45 -58 -102 -71 -131 -232
Consolidated Net Income / (Loss)		 6.35 -22 -18 -53 -57 -45 -58 -102 -71 -131 -232
Depreciation Expense		 0.11 0.15 0.09 0.17 0.14 0.19 0.31 0.40 0.46 1.54 2.31
Amortization Expense		 0.87 0.84 -4.87 1.19 3.06 3.21 3.09 1.49 -0.86 -5.95 -4.83
Non-Cash Adjustments To Reconcile Net Income		 1.96 2.16 2.46 29 9.48 7.43 6.66 38 14 38 28
Changes in Operating Assets and Liabilities, net		 1.01 2.07 0.32 0.93 -13 20 -1.74 -3.09 59 -29 -34
Net Cash From Investing Activities		 -6.73 -4.46 14 -17 -0.21 -0.36 -33 -17 -3.32 -219 69
Net Cash From Continuing Investing Activities		 -6.73 -4.46 14 -17 -0.21 -0.36 -33 -17 -3.32 -219 69
Purchase of Property, Plant & Equipment		 -0.16 -0.11 -0.15 -0.11 -0.21 -0.36 -0.16 -2.15 -3.48 -4.05 -3.28
Purchase of Investments		 -10 -18 -5.05 0.00 - 0.00 -33 -139 -55 -398 -252
Sale of Property, Plant & Equipment		 0.00 0.00 0.03 0.00 - - - - - 0.00 0.16
Sale and/or Maturity of Investments		 3.65 13 19 0.00 - - 0.00 124 55 183 324
Net Cash From Financing Activities		 0.24 17 8.50 61 34 37 217 -0.69 187 164 174
Net Cash From Continuing Financing Activities		 0.24 17 8.50 61 34 37 217 -0.69 187 164 174
Repayment of Debt		 - 0.00 0.00 -1.35 -24 -15 0.00 -74 -47 0.00 0.00
Repurchase of Common Equity		 - - - - - - 0.00 -0.60 -0.45 -0.67 -0.54
Issuance of Debt		 - 0.00 0.00 20 50 - 0.00 74 5.30 0.00 0.00
Issuance of Common Equity		 0.00 17 8.40 42 23 50 217 0.00 226 163 173
Other Financing Activities, net		 0.24 0.49 0.10 0.50 -15 2.20 0.08 -0.04 3.17 1.38 0.75
Effect of Exchange Rate Changes		 -0.01 -0.02 - - - 0.00 0.00 0.00 0.00 0.00 0.00
Cash Interest Paid		 - 0.00 0.00 0.26 4.87 5.51 4.85 2.60 1.41 0.00 0.00

Quarterly Cash Flow Statements for Eyepoint Pharmaceuticals

This table details how cash moves in and out of Eyepoint Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -6.56 148 -10 -180 -11 20 -15 -14 3.43 27 -24
Net Cash From Operating Activities		 -15 -23 -31 -20 -39 -36 -53 -63 -59 -65 -81
Net Cash From Continuing Operating Activities		 -15 -23 -31 -20 -39 -36 -53 -63 -59 -65 -81
Net Income / (Loss) Continuing Operations		 -13 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85
Consolidated Net Income / (Loss)		 -13 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85
Depreciation Expense		 0.12 0.11 0.30 0.36 0.41 0.47 0.50 0.54 0.58 0.70 0.64
Amortization Expense		 -0.04 -0.52 -0.58 -1.69 -1.88 -1.81 -1.73 -1.20 -0.95 -0.94 -0.78
Non-Cash Adjustments To Reconcile Net Income		 4.10 3.12 13 8.70 7.45 7.90 7.82 6.40 6.95 6.73 12
Changes in Operating Assets and Liabilities, net		 -6.76 -12 -15 3.28 -16 -1.01 -15 -8.90 -6.20 -3.92 -7.21
Net Cash From Investing Activities		 -1.72 -47 21 -160 16 -96 40 48 55 -75 59
Net Cash From Continuing Investing Activities		 -1.72 -47 21 -160 16 -96 40 48 55 -75 59
Purchase of Property, Plant & Equipment		 -1.72 -0.88 -1.19 -0.90 -1.57 -0.38 -0.28 -1.22 -0.80 -0.99 -1.00
Purchase of Investments		 - -49 0.00 -185 -49 -164 -39 -54 -9.82 -149 -9.95
Sale and/or Maturity of Investments		 - 3.00 22 26 67 69 79 104 66 75 70
Net Cash From Financing Activities		 10 218 0.12 0.33 12 152 -0.95 0.24 7.40 167 -2.61
Net Cash From Continuing Financing Activities		 10 218 0.12 0.33 12 152 -0.95 0.24 7.40 167 -2.61
Repayment of Debt		 - - 0.00 - -0.07 0.07 0.00 -0.05 0.05 - 0.00
Repurchase of Common Equity		 -0.42 -0.04 -0.09 0.09 -0.31 -0.37 -0.29 - - -0.25 -0.30
Issuance of Debt		 - - 0.00 - - - 0.00 - - - 0.00
Issuance of Common Equity		 9.97 216 0.00 - 12 152 0.00 - 6.66 167 0.00
Other Financing Activities, net		 0.80 2.32 0.20 0.55 0.17 0.46 -0.66 0.29 0.69 0.42 -2.32
Cash Interest Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Eyepoint Pharmaceuticals

This table presents Eyepoint Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 32 32 19 78 73 92 263 180 355 418 364
Total Current Assets		 30 30 18 48 42 63 238 173 345 383 329
Cash & Equivalents		 19 15 17 45 22 45 179 96 281 100 102
Short-Term Investments		 9.41 14 - - - 0.00 33 49 50 271 204
Accounts Receivable		 0.62 0.49 0.25 0.63 11 9.45 18 16 0.81 0.61 0.65
Inventories, net		 - - 0.00 0.28 2.14 5.34 3.62 2.89 3.91 2.31 1.81
Prepaid Expenses		 0.68 0.48 0.59 1.43 6.00 3.42 4.22 9.86 9.04 9.48 20
Plant, Property, & Equipment, net		 0.34 0.29 0.31 0.29 0.36 0.63 0.48 1.36 5.25 8.18 9.02
Total Noncurrent Assets		 2.19 1.37 0.62 30 31 28 25 6.19 5.13 27 26
Intangible Assets		 1.93 1.10 0.36 30 28 25 23 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 0.12 0.11 0.11 0.00 3.08 2.61 2.25 6.04 4.98 27 26
Other Noncurrent Nonoperating Assets		 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Total Liabilities & Shareholders' Equity		 32 32 19 78 73 92 263 180 355 418 364
Total Liabilities		 9.00 11 5.34 41 65 73 79 84 89 82 58
Total Current Liabilities		 3.35 5.09 5.29 21 12 15 24 35 63 49 37
Short-Term Debt		 - - - - - - 0.00 10 0.00 0.00 0.00
Accounts Payable		 0.74 1.36 1.02 2.64 4.19 4.81 7.39 5.92 6.50 12 10
Accrued Expenses		 2.57 3.58 4.22 19 6.83 8.45 14 16 18 18 24
Current Deferred Revenue		 0.03 0.15 0.05 0.03 0.02 0.95 1.07 1.21 39 18 0.00
Other Current Liabilities		 - - - 0.00 0.48 0.69 0.78 0.58 0.65 1.44 2.14
Total Noncurrent Liabilities		 5.65 5.65 0.05 19 53 58 55 49 26 33 21
Long-Term Debt		 - - 0.00 18 47 38 37 29 0.00 0.00 0.00
Noncurrent Deferred Revenue		 5.65 5.65 - - 0.00 16 15 14 21 11 0.00
Other Noncurrent Operating Liabilities		 - - 0.05 1.46 5.90 4.70 4.21 6.58 4.91 22 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 23 21 13 38 8.33 19 184 96 266 337 306
Total Preferred & Common Equity		 23 21 13 38 8.33 19 184 96 266 337 306
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 23 21 13 38 8.33 19 184 96 266 337 306
Common Stock		 293 312 323 445 473 528 753 767 1,008 1,208 1,410
Retained Earnings		 -271 -292 -311 -408 -465 -511 -569 -671 -742 -873 -1,105
Accumulated Other Comprehensive Income / (Loss)		 0.95 0.85 0.83 0.84 0.84 0.84 0.84 0.79 0.86 1.03 0.96

Quarterly Balance Sheets for Eyepoint Pharmaceuticals

This table presents Eyepoint Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 220 155 176 160 329 324 301 363 301 252 288
Total Current Assets		 192 146 167 150 318 295 269 327 265 216 250
Cash & Equivalents		 75 106 140 133 271 91 80 85 71 75 78
Short-Term Investments		 82 17 2.94 2.98 28 189 174 233 185 129 145
Accounts Receivable		 21 10 11 0.48 3.02 1.38 0.38 0.44 0.63 1.05 1.16
Inventories, net		 3.53 4.07 4.26 4.58 4.26 3.67 2.81 2.13 2.68 2.11 1.25
Prepaid Expenses		 10 9.08 9.37 9.09 11 9.64 12 6.22 6.22 8.93 25
Plant, Property, & Equipment, net		 1.02 2.61 2.87 4.48 6.68 6.90 8.39 8.04 8.76 8.86 9.48
Total Noncurrent Assets		 27 5.93 5.66 5.40 4.86 22 24 28 27 27 29
Intangible Assets		 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 6.32 5.78 5.51 5.25 4.71 22 24 27 27 27 29
Other Noncurrent Nonoperating Assets		 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Total Liabilities & Shareholders' Equity		 220 155 176 160 329 324 301 363 301 252 288
Total Liabilities		 84 76 118 101 79 96 82 64 55 52 58
Total Current Liabilities		 34 27 69 64 63 62 49 42 33 30 37
Short-Term Debt		 10 5.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable		 6.11 9.45 11 9.58 7.08 14 7.34 16 20 10 19
Accrued Expenses		 16 10 15 13 16 13 14 18 11 18 16
Current Deferred Revenue		 1.17 1.24 42 40 38 33 26 5.12 0.00 0.00 0.00
Other Current Liabilities		 0.50 0.77 0.97 1.06 1.18 1.13 1.29 1.97 2.01 2.08 2.21
Total Noncurrent Liabilities		 50 49 49 38 17 34 33 22 22 21 20
Long-Term Debt		 29 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Noncurrent Deferred Revenue		 14 13 44 32 12 12 11 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 6.84 6.32 5.46 5.19 4.62 22 22 22 22 21 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 136 78 57 59 250 228 219 298 246 200 230
Total Preferred & Common Equity		 136 78 57 59 250 228 219 298 246 200 230
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 136 78 57 59 250 228 219 298 246 200 230
Common Stock		 764 770 772 786 1,021 1,030 1,049 1,216 1,223 1,237 1,419
Retained Earnings		 -628 -693 -715 -728 -771 -802 -832 -918 -978 -1,037 -1,190
Accumulated Other Comprehensive Income / (Loss)		 0.65 0.84 0.84 0.84 0.84 0.79 1.17 0.92 0.83 0.92 0.80

Annual Metrics And Ratios for Eyepoint Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eyepoint Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 29,412,365.00 34,172,919.00 39,268,692.00 94,855,705.00 108,117,440.00 143,515,338.00 28,771,264.00 - - - 82,787,220.00
DEI Adjusted Shares Outstanding		 2,941,236.00 3,417,292.00 3,926,869.00 9,485,570.00 10,811,744.00 14,351,534.00 28,771,264.00 - - - 82,787,220.00
DEI Earnings Per Adjusted Shares Outstanding		 2.16 -6.31 -4.71 -9.08 -5.25 -6.33 -2.03 - - - -2.80
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 6.33 -15 -13 -27 -34 -26 -39 -70 -53 -102 -170
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -19.73% -30.34% -55.67%
Earnings before Interest and Taxes (EBIT)		 6.44 -22 -18 -84 -47 -45 -55 -98 -68 -131 -232
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 7.42 -21 -23 -82 -44 -42 -52 -96 -69 -135 -234
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 8.14 -12 -18 -41 -57 -4.37 -36 -52 3.77 -132 -205
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.32 -8.26 -3.71 9.84 33 11 9.23 -8.56 -65 -35 -0.12
Increase / (Decrease) in Invested Capital		 -1.81 -2.94 4.55 14 23 -22 -2.23 -18 -56 30 34
Book Value per Share		 $0.79 $0.61 $0.34 $0.40 $0.08 $0.13 $6.41 $2.83 $7.54 $4.93 $3.70
Tangible Book Value per Share		 $0.73 $0.58 $0.33 $0.08 ($0.18) ($0.05) $5.62 $2.83 $7.54 $4.93 $3.70
Total Capital		 23 21 13 55 56 57 221 136 266 337 306
Total Debt		 0.00 0.00 0.00 18 47 38 37 40 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 18 47 38 37 29 0.00 0.00 0.00
Net Debt		 -29 -29 -17 -28 25 -6.93 -175 -105 -331 -371 -306
Capital Expenditures (CapEx)		 0.16 0.11 0.11 0.11 0.21 0.36 0.16 2.15 3.48 4.05 3.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.05 -4.12 -4.45 -19 7.98 3.32 2.53 4.19 -50 -37 -14
Debt-free Net Working Capital (DFNWC)		 26 25 12 26 30 48 214 149 282 334 292
Net Working Capital (NWC)		 26 25 12 26 30 48 214 138 282 334 292
Net Nonoperating Expense (NNE)		 -0.02 6.31 5.48 59 23 19 20 33 18 29 62
Net Nonoperating Obligations (NNO)		 -29 -29 -17 -28 25 -7.08 -175 -105 -331 -371 -306
Total Depreciation and Amortization (D&A)		 0.98 1.00 -4.78 1.36 3.20 3.39 3.40 1.89 -0.39 -4.41 -2.52
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.20 ($6.80) ($5.20) ($11.50) ($5.40) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Adjusted Weighted Average Basic Shares Outstanding		 2.94M 3.16M 3.53M 7.45M 12.47M 28.74M 34.04M 37.32M 38.90M 56.30M 73.25M
Adjusted Diluted Earnings per Share		 $2.10 ($6.80) ($5.20) ($11.50) ($5.40) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Adjusted Weighted Average Diluted Shares Outstanding		 3.06M 3.16M 3.53M 7.45M 12.47M 28.74M 34.04M 37.32M 38.90M 56.30M 73.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($5.20) ($11.50) ($5.40) ($3.54) ($2.03) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.94M 3.42M 3.94M 4.62M 10.43M 12.84M 28.76M 34.30M 49.83M 68.73M 83.43M
Normalized Net Operating Profit after Tax (NOPAT)		 6.33 -15 -13 -27 -34 -26 -39 -55 -53 -102 -170
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Eyepoint Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eyepoint Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 68,728,760.00 68,811,736.00 68,927,425.00 82,787,220.00 83,431,950.00
DEI Adjusted Shares Outstanding		 - - - - - - 68,728,760.00 68,811,736.00 68,927,425.00 82,787,220.00 83,431,950.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.66 -0.86 -0.87 -0.82 -1.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 51.84% 33.18% 52.08% 4.09% -30.77% -17.39% 109.29% -43.73% -90.82% - -97.15%
EBITDA Growth		 27.37% 66.20% -44.24% -52.71% -145.92% -195.56% -57.10% -86.58% -94.97% - -83.12%
EBIT Growth		 28.98% 67.15% -43.89% -45.83% -132.80% -194.63% -54.33% -92.48% -103.44% - -87.81%
NOPAT Growth		 21.74% 62.61% -54.59% -51.78% -127.45% -176.62% -46.57% -80.13% -89.40% - -78.61%
Net Income Growth		 31.53% 67.55% -38.37% -34.49% -132.80% -193.63% -54.33% -92.78% -103.44% - -87.70%
EPS Growth		 32.65% 72.41% 1.79% 4.92% -63.64% -103.13% -18.18% -46.55% -57.41% - -52.31%
Operating Cash Flow Growth		 -15.74% -83.58% -85.16% -135.39% -156.70% -55.13% -70.41% -210.18% -52.08% - -51.64%
Free Cash Flow Firm Growth		 486.90% 449.86% 67.31% -164.48% -175.76% -238.13% -482.93% -49.15% -14.38% - -39.15%
Invested Capital Growth		 -515.39% -658.09% -417.48% 39.02% 54.59% 46.73% 59.75% 81.05% 88.67% - 138.99%
Revenue Q/Q Growth		 66.96% -7.72% -16.71% -18.89% 11.05% 10.11% 111.02% -78.19% -81.89% - 12.44%
EBITDA Q/Q Growth		 40.47% -15.08% -104.88% -8.80% 4.13% -38.30% -8.90% -29.22% -0.19% - -25.71%
EBIT Q/Q Growth		 40.33% -11.13% -108.93% -5.27% 4.75% -40.65% -9.44% -31.28% -0.67% - -25.96%
NOPAT Q/Q Growth		 36.74% -13.59% -103.75% -3.68% 5.20% -38.14% -7.95% -27.42% 0.32% - -24.00%
Net Income Q/Q Growth		 44.97% -11.79% -107.70% -5.27% 4.75% -41.00% -9.17% -31.49% -0.51% - -25.47%
EPS Q/Q Growth		 45.90% 3.03% -71.88% -5.45% 6.90% -20.37% 0.00% -30.77% 0.00% - -20.73%
Operating Cash Flow Q/Q Growth		 -126.66% -51.99% -34.89% 35.27% -93.42% 8.15% -48.18% -17.83% 5.17% - -23.83%
Free Cash Flow Firm Q/Q Growth		 -3.44% -47.90% -62.87% -445.18% -13.46% 5.02% -2.94% -34.44% 12.99% - -6.10%
Invested Capital Q/Q Growth		 9.23% 16.33% 23.60% -5.10% 32.41% 1.84% 42.28% 50.50% 59.59% - 6,422.76%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 92.09% 125.91% 93.50% 85.22% 93.01% 124.99% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 -82.46% -102.84% -252.96% -339.31% -292.94% -367.95% -189.88% -1,125.00% -6,222.26% - -12,216.09%
Operating Margin		 -94.71% -116.58% -285.18% -364.52% -311.17% -390.40% -199.72% -1,166.83% -6,420.81% - -12,532.47%
EBIT Margin		 -82.96% -99.91% -250.63% -325.27% -278.99% -356.36% -184.82% -1,112.56% -6,183.44% - -12,195.69%
Profit (Net Income) Margin		 -82.96% -100.51% -250.63% -325.27% -278.99% -357.26% -184.82% -1,114.31% -6,183.44% - -12,188.51%
Tax Burden Percent		 100.00% 100.59% 100.00% 100.00% 100.00% 100.22% 100.00% 100.16% 100.00% - 99.94%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.03% 100.00% 100.00% 100.00% - 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -102.73% -39.04% -48.07% -60.81% -74.68% -43.42% -53.54% -73.95% -98.23% - -102.71%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -2,893.16%
Operating Return on Assets (OROA)		 -18.54% -17.17% -51.82% -65.58% -55.33% -39.87% -29.94% -184.65% -947.52% - -285.37%
Return on Assets (ROA)		 -18.54% -17.27% -51.82% -65.58% -55.33% -39.97% -29.94% -184.94% -947.52% - -285.21%
Return on Common Equity (ROCE)		 -102.73% -39.04% -48.07% -60.81% -74.68% -43.42% -53.54% -73.95% -98.23% - -102.71%
Return on Equity Simple (ROE_SIMPLE)		 -170.84% 0.00% -31.57% -38.03% -47.35% 0.00% -49.19% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -10 -11 -23 -24 -23 -32 -34 -44 -43 -49 -61
NOPAT Margin		 -66.30% -81.61% -199.63% -255.17% -217.82% -273.28% -139.80% -816.78% -4,494.57% - -8,772.73%
Net Nonoperating Expense Percent (NNEP)		 -2.00% -1.22% -3.08% -3.14% -3.30% -2.77% -3.56% -5.92% -7.12% - -8.79%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.30% - - - -9.41% -11.46% -17.71% -21.69% -16.09% -26.49%
Cost of Revenue to Revenue		 7.91% -25.91% 6.50% 14.78% 6.99% -24.99% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 69.44% 80.18% 120.69% 134.54% 123.24% 108.19% 56.75% 222.43% 1,500.00% - 2,190.09%
R&D to Revenue		 114.22% 127.97% 257.95% 314.68% 280.71% 374.72% 239.54% 1,040.65% 4,943.48% - 10,366.09%
Operating Expenses to Revenue		 186.80% 242.49% 378.69% 449.74% 404.18% 515.39% 299.72% 1,266.83% 6,520.81% - 12,632.47%
Earnings before Interest and Taxes (EBIT)		 -13 -14 -29 -31 -29 -41 -45 -59 -60 -67 -85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -14 -30 -32 -31 -43 -46 -60 -60 -68 -85
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.77 3.06 4.12 1.98 1.95 1.51 1.25 2.63 4.90 - 4.67
Price to Tangible Book Value (P/TBV)		 4.77 3.06 4.12 1.98 1.95 1.51 1.25 2.63 4.90 - 4.67
Price to Revenue (P/Rev)		 6.57 17.73 20.59 8.99 9.35 11.75 6.65 12.48 23.18 - 141.24
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 109.67
Enterprise Value to Revenue (EV/Rev)		 3.37 10.54 14.61 3.43 3.80 3.18 0.97 7.55 18.36 - 112.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.58 258.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 5.86 128.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.30 -1.20 -1.18 -1.48 -1.41 -1.17 -1.13 -1.13 -1.09 - -1.02
Leverage Ratio		 1.95 1.48 1.47 1.75 1.66 1.28 1.26 1.32 1.32 - 1.23
Compound Leverage Factor		 1.95 1.48 1.47 1.75 1.66 1.28 1.26 1.32 1.32 - 1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -4.06 3.54 5.30 0.07 -0.04 1.54 0.63 2.95 5.93 - 5.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.35 5.45 5.08 4.75 5.50 7.81 7.85 8.00 7.18 - 6.66
Quick Ratio		 2.14 5.25 4.83 4.53 5.21 7.57 7.65 7.73 6.81 - 5.97
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 86 45 17 -58 -65 -62 -64 -86 -75 -84 -89
Operating Cash Flow to CapEx		 -883.95% -2,617.10% -2,610.64% -2,242.00% -2,479.54% -9,335.68% -19,246.38% -5,130.25% -7,437.84% - -8,079.14%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -4,427.31 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -2,560.64 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -2,588.07 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.22 0.17 0.21 0.20 0.20 0.11 0.16 0.17 0.15 - 0.02
Accounts Receivable Turnover		 3.98 5.64 7.45 8.18 106.19 61.29 32.42 51.90 59.51 - 9.52
Inventory Turnover		 2.51 0.00 1.14 1.10 1.05 0.00 0.00 0.00 0.00 - 0.75
Fixed Asset Turnover		 15.48 13.92 10.77 10.31 7.10 6.45 7.61 6.63 4.91 - 0.87
Accounts Payable Turnover		 1.30 0.00 0.57 0.35 0.46 0.00 0.00 0.00 0.00 - 0.07
Days Sales Outstanding (DSO)		 91.67 64.67 49.03 44.64 3.44 5.96 11.26 7.03 6.13 - 38.33
Days Inventory Outstanding (DIO)		 145.31 0.00 319.90 332.06 346.07 0.00 0.00 0.00 0.00 - 489.03
Days Payable Outstanding (DPO)		 281.23 0.00 635.16 1,046.99 793.13 0.00 0.00 0.00 0.00 - 5,099.00
Cash Conversion Cycle (CCC)		 -44.25 64.67 -266.23 -670.29 -443.63 5.96 11.26 7.03 6.13 - -4,571.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -78 -65 -50 -52 -35 -35 -20 -9.87 -3.99 -0.12 7.78
Invested Capital Turnover		 -1.44 -1.25 -1.69 -0.73 -0.81 -0.87 -1.61 -1.68 -2.16 - -1.25
Increase / (Decrease) in Invested Capital		 -96 -56 -40 33 42 30 30 42 31 34 28
Enterprise Value (EV)		 144 485 731 173 174 138 54 392 778 - 853
Market Capitalization		 280 816 1,030 453 428 508 373 648 982 - 1,075
Book Value per Share		 $1.68 $7.54 $5.02 $4.38 $4.09 $4.93 $4.34 $3.58 $2.90 $3.70 $2.76
Tangible Book Value per Share		 $1.68 $7.54 $5.02 $4.38 $4.09 $4.93 $4.34 $3.58 $2.90 $3.70 $2.76
Total Capital		 59 266 250 228 219 337 298 246 200 306 230
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -136 -331 -299 -280 -254 -371 -318 -256 -204 -306 -223
Capital Expenditures (CapEx)		 1.72 0.88 1.19 0.90 1.57 0.38 0.28 1.22 0.80 0.99 1.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -50 -50 -44 -47 -34 -37 -33 -24 -18 -14 -11
Debt-free Net Working Capital (DFNWC)		 86 282 255 233 220 334 285 232 186 292 212
Net Working Capital (NWC)		 86 282 255 233 220 334 285 232 186 292 212
Net Nonoperating Expense (NNE)		 2.53 2.65 5.96 6.64 6.44 9.73 11 16 16 18 24
Net Nonoperating Obligations (NNO)		 -136 -331 -299 -280 -254 -371 -318 -256 -204 -306 -223
Total Depreciation and Amortization (D&A)		 0.08 -0.41 -0.27 -1.33 -1.47 -1.34 -1.24 -0.66 -0.38 -0.25 -0.14
Debt-free, Cash-free Net Working Capital to Revenue		 -116.98% -107.59% -88.40% -94.10% -74.46% -84.71% -58.68% -45.58% -42.54% - -137.92%
Debt-free Net Working Capital to Revenue		 202.87% 611.80% 510.06% 462.04% 480.73% 772.44% 509.09% 447.18% 439.33% - 2,784.92%
Net Working Capital to Revenue		 202.87% 611.80% 510.06% 462.04% 480.73% 772.44% 509.09% 447.18% 439.33% - 2,784.92%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 38.34M 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 38.34M 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.31M 49.83M 52.08M 53.52M 68.25M 68.73M 68.81M 68.93M 82.79M 83.43M 83.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -11 -23 -24 -23 -32 -34 -44 -43 -49 -61
Normalized NOPAT Margin		 -66.30% -81.61% -199.63% -255.17% -217.82% -273.28% -139.80% -816.78% -4,494.57% - -8,772.73%
Pre Tax Income Margin		 -82.96% -99.91% -250.63% -325.27% -278.99% -356.48% -184.82% -1,112.56% -6,183.44% - -12,195.69%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -2,949.64 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -2,261.95 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -2,977.07 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -2,289.38 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 -0.41% -0.64% -0.68% -0.52% -0.33% -0.51% -0.60% -0.37% -0.32% - -0.20%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from EyePoint Pharmaceuticals (NASDAQ: EYPT) quarterly filings, focusing on the last four years of data and highlighting trends through Q4 2025.

  • No long-term debt on recent balance sheets: Long-Term Debt is reported as 0.0 in recent quarters, reducing interest burden and leverage risk.
  • Material equity financing in Q4 2025: Issuance of Common Equity totaled $166,787,000, expanding EyePoint’s equity base.
  • Strong financing activity in Q4 2025: Net cash from financing activities was +$166,957,000, driven by equity issuance and related financing.
  • Solid equity cushion: Total Common Equity around $200.2M (about $200,182,000) in the latest period, indicating a sizable equity base relative to liabilities.
  • Near-term liquidity improved in Q4 2025: Net change in cash for the quarter was +$27,244,000, aided by financing inflows.
  • Revenue remains modest and volatile: Operating revenue in Q4 2025 was $0.619M, with quarterly revenue varying significantly across 2023–2025, suggesting no clear, stable top-line trajectory.
  • Investing cash flows show timing-driven variability: Cash flows from investing activities swing between inflows and outflows across quarters, reflecting asset sales and purchases rather than a steady pattern.
  • Earnings per share trend remains negative: Basic and diluted EPS are negative across recent quarters (for example, about -$0.82 in Q4 2025 and -$0.85 in Q3 2025), signaling ongoing losses per share.
  • Persistent net losses: Net income / loss from continuing operations was -$67.6M in Q4 2025, -$59.7M in Q3 2025, -$59.4M in Q2 2025, and -$45.2M in Q1 2025.
  • Operating cash flow remains negative: Net cash from continuing operating activities was -$65.0M in Q4 2025 (and similarly negative in prior quarters), indicating ongoing cash burn from operations.
  • Bottom-line profitability and near-term cash burn: The company continues to post losses at the net income line, with negative pretax income in multiple quarters and substantial cash outflows from operations.
05/26/26 03:40 AM ETAI Generated. May Contain Errors.

Eyepoint Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Eyepoint Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Eyepoint Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$231.96 million in 2025, falling from $6.35 million in 2015. The previous period was -$130.87 million in 2024. See Eyepoint Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Eyepoint Pharmaceuticals' total operating income in 2025 was -$243.43 million, based on the following breakdown:
  • Total Gross Profit: $29.31 million
  • Total Operating Expenses: $272.74 million

Over the last 10 years, Eyepoint Pharmaceuticals' total revenue changed from $26.57 million in 2015 to $31.37 million in 2025, a change of 18.1%.

Eyepoint Pharmaceuticals' total liabilities were at $57.88 million at the end of 2025, a 29.4% decrease from 2024, and a 543.2% increase since 2015.

In the past 10 years, Eyepoint Pharmaceuticals' cash and equivalents has ranged from $15.31 million in 2016 to $281.26 million in 2023, and is currently $101.82 million as of their latest financial filing in 2025.

Over the last 10 years, Eyepoint Pharmaceuticals' book value per share changed from 0.79 in 2015 to 3.70 in 2025, a change of 365.4%.


Related Companies

Financial statements for NASDAQ:EYPT last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel